The reporting of observational studies of drug effectiveness and safety: recommendations to extend existing guidelines
暂无分享,去创建一个
G. Guyatt | G. Collins | R. Kassam | L. Lynd | M. Mansournia | M. Etminan | H. Tremlett | M. Sadatsafavi | J. Cragg | C. Jutzeler | A. Gershon | M. D. de Vera | T. Kendzerska | M. Harrison | L. Azoulay | F. Warner | F. Lalji | B. Tong | Fawziah Lalji | Tetyana Kendzerska
[1] M. Rezaeian. Standards for Reporting Qualitative Research , 2019 .
[2] F. Geisler,et al. A Longitudinal Study of the Neurologic Safety of Acute Baclofen Use After Spinal Cord Injury , 2019, Neurotherapeutics.
[3] L. Lynd,et al. Use of biologics during pregnancy and risk of serious infections in the mother and baby: a Canadian population-based cohort study , 2019, BMJ Open.
[4] Olaf Klungel,et al. The reporting of studies conducted using observational routinely collected health data statement for pharmacoepidemiology (RECORD-PE) , 2018, British Medical Journal.
[5] O. Hankivsky,et al. Beyond sex and gender difference in funding and reporting of health research , 2018, Research Integrity and Peer Review.
[6] N. Qizilbash,et al. A review of studies evaluating the effectiveness of risk minimisation measures in Europe using the European Union electronic Register of Post‐Authorization Studies , 2018, Pharmacoepidemiology and drug safety.
[7] S. Schroter,et al. Frequency of reporting on patient and public involvement (PPI) in research studies published in a general medical journal: a descriptive study , 2018, BMJ Open.
[8] Harold C. Sox,et al. Recommendations for Good Procedural Practices for Real-World Data Studies of Treatment Effectiveness and/or Comparative Effectiveness Designed to Inform Health Care Decisions: Report of the Joint ISPOR-ISPE Special Task Force on Real-World Evidence in Health Care Decision Making , 2017 .
[9] G. Collins,et al. Handling time varying confounding in observational research , 2017, British Medical Journal.
[10] L. Lynd,et al. The Impact of Statin Drug Use on All‐Cause Mortality in Patients With COPD: A Population‐Based Cohort Study , 2017, Chest.
[11] David Madigan,et al. Good practices for real‐world data studies of treatment and/or comparative effectiveness: Recommendations from the joint ISPOR‐ISPE Special Task Force on real‐world evidence in health care decision making , 2017, Pharmacoepidemiology and drug safety.
[12] D. G. Altman,et al. GRIPP2 reporting checklists: tools to improve reporting of patient and public involvement in research , 2017, Research Involvement and Engagement.
[13] M. Orho-Melander,et al. Type 2 diabetes, adiposity and cancer morbidity and mortality risk taking into account competing risk of noncancer deaths in a prospective cohort setting , 2017, International journal of cancer.
[14] G. Guyatt,et al. Adjusted Analyses in Studies Addressing Therapy and Harm: Users’ Guides to the Medical Literature , 2017, JAMA.
[15] N. Jewell,et al. Case–control matching: effects, misconceptions, and recommendations , 2017, European Journal of Epidemiology.
[16] Johannes B Reitsma,et al. STARD 2015 guidelines for reporting diagnostic accuracy studies: explanation and elaboration , 2016, BMJ Open.
[17] Jessie K. Edwards,et al. Methodologic Issues when Estimating Risks in Pharmacoepidemiology , 2016, Current Epidemiology Reports.
[18] C. Chambers,et al. Constructing Causal Diagrams for Common Perinatal Outcomes: Benefits, Limitations and Motivating Examples with Maternal Antidepressant Use in Pregnancy. , 2016, Paediatric and perinatal epidemiology.
[19] David Moher,et al. CONSORT extension for reporting N-of-1 trials (CENT) 2015 Statement. , 2016, Journal of clinical epidemiology.
[20] Kit C.B. Roes,et al. Methods to control for unmeasured confounding in pharmacoepidemiology: an overview , 2016, International Journal of Clinical Pharmacy.
[21] Susan Michie,et al. Explanation and elaboration of the SQUIRE (Standards for Quality Improvement Reporting Excellence) Guidelines, V.2.0: examples of SQUIRE elements in the healthcare improvement literature , 2016, BMJ Quality & Safety.
[22] Melissa C Brouwers,et al. The AGREE Reporting Checklist: a tool to improve reporting of clinical practice guidelines , 2016, British Medical Journal.
[23] Douglas G Altman,et al. Inverse probability weighting , 2016, British Medical Journal.
[24] David Moher,et al. The REporting of Studies Conducted Using Observational Routinely-Collected Health Data (RECORD) Statement: Methods for Arriving at Consensus and Developing Reporting Guidelines , 2015, PloS one.
[25] Eric E. Smith,et al. Real world effectiveness of warfarin among ischemic stroke patients with atrial fibrillation: observational analysis from Patient-Centered Research into Outcomes Stroke Patients Prefer and Effectiveness Research (PROSPER) study , 2015, BMJ : British Medical Journal.
[26] O. Hanon,et al. Antihypertensive Drugs, Prevention of Cognitive Decline and Dementia: A Systematic Review of Observational Studies, Randomized Controlled Trials and Meta-Analyses, with Discussion of Potential Mechanisms , 2015, CNS Drugs.
[27] Clement J. McDonald,et al. Visualization of Patient Prescription History Data in Emergency Care , 2014, AMIA.
[28] Bridget C. O’Brien,et al. Standards for Reporting Qualitative Research: A Synthesis of Recommendations , 2014, Academic medicine : journal of the Association of American Medical Colleges.
[29] Estimation of Drug Effectiveness by Modeling Three Time-Dependent Covariates: An Application to Data on Cardioprotective Medications in the Chronic Dialysis Population , 2014, Statistics in biopharmaceutical research.
[30] D. Moher,et al. The CARE guidelines: consensus-based clinical case report guideline development. , 2014, Journal of clinical epidemiology.
[31] M. Drummond,et al. Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement. , 2013, BMJ.
[32] D. Rennie,et al. SPIRIT 2013 statement: defining standard protocol items for clinical trials. , 2013, Annals of internal medicine.
[33] K. Meador,et al. Fetal antiepileptic drug exposure and cognitive outcomes at age 6 years (NEAD study): a prospective observational study , 2013, The Lancet Neurology.
[34] Samy Suissa,et al. Metformin and the Risk of Cancer , 2012, Diabetes Care.
[35] J. Ioannidis,et al. STrengthening the Reporting of OBservational studies in Epidemiology — Molecular Epidemiology STROBE-ME: an extension of the STROBE statement [J Clin Epidemiol 2011;64(12):1350–1363] , 2012 .
[36] Rebecca M. Jordan-Young,et al. Beyond a catalogue of differences: a theoretical frame and good practice guidelines for researching sex/gender in human health. , 2012, Social science & medicine.
[37] Joy L. Johnson,et al. Sex and gender reporting in health research: why Canada should be a leader. , 2012, Canadian journal of public health = Revue canadienne de sante publique.
[38] Elizabeth Murphy,et al. The importance of direct patient reporting of suspected adverse drug reactions: a patient perspective. , 2011, British journal of clinical pharmacology.
[39] J. Ioannidis,et al. STrengthening the Reporting of OBservational studies in Epidemiology – Molecular Epidemiology (STROBE-ME): An Extension of the STROBE Statement , 2011, PLoS medicine.
[40] Douglas G. Altman,et al. WITHDRAWN: CONSORT 2010 statement: Updated guidelines for reporting parallel group randomised trials , 2010 .
[41] Paolo Vineis,et al. STrengthening the Reporting of OBservational studies in Epidemiology - Molecular Epidemiology (STROBE-ME): an extension of the STROBE statement. , 2011, Preventive medicine.
[42] C. Clarke,et al. Systematic review of levodopa dose equivalency reporting in Parkinson's disease , 2010, Movement disorders : official journal of the Movement Disorder Society.
[43] Tony Tse,et al. Registration of observational studies: Is it time? , 2010, Canadian Medical Association Journal.
[44] Gordon B. Drummond,et al. ARRIVE: new guidelines for reporting animal research , 2010, Experimental physiology.
[45] I. Cuthill,et al. Animal Research: Reporting In Vivo Experiments: The ARRIVE Guidelines , 2010, British journal of pharmacology.
[46] R. Bender,et al. Estimating adjusted risk difference (RD) and number needed to treat (NNT) measures in the Cox regression model , 2010, Statistics in medicine.
[47] D. Moher,et al. CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials , 2010, BMC medicine.
[48] Ethan Basch,et al. The missing voice of patients in drug-safety reporting. , 2010, The New England journal of medicine.
[49] D. Moher,et al. CONSORT 2010 statement: Updated guidelines for reporting parallel group randomised trials , 2010, Journal of pharmacology & pharmacotherapeutics.
[50] Trish Groves,et al. Registration of observational studies , 2010, BMJ : British Medical Journal.
[51] D. Moher,et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement , 2009, BMJ : British Medical Journal.
[52] S. Cole,et al. Overadjustment Bias and Unnecessary Adjustment in Epidemiologic Studies , 2009, Epidemiology.
[53] J. Ioannidis,et al. Strengthening the reporting of genetic association studies (STREGA): an extension of the strengthening the reporting of observational studies in epidemiology (STROBE) statement. , 2009, Journal of clinical epidemiology.
[54] R. Tannen,et al. Use of primary care electronic medical record database in drug efficacy research on cardiovascular outcomes: comparison of database and randomised controlled trial findings , 2009, BMJ : British Medical Journal.
[55] D. Mattison,et al. Sex Differences in Pharmacokinetics and Pharmacodynamics , 2009, Clinical pharmacokinetics.
[56] Ian Shrier,et al. Reducing bias through directed acyclic graphs , 2008 .
[57] S. Suissa. Immeasurable time bias in observational studies of drug effects on mortality. , 2008, American journal of epidemiology.
[58] C. Rutter,et al. De Facto Long-term Opioid Therapy for Noncancer Pain , 2008, The Clinical journal of pain.
[59] Iveta Simera,et al. EQUATOR: reporting guidelines for health research , 2008, Open medicine : a peer-reviewed, independent, open-access journal.
[60] Douglas G Altman,et al. Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. , 2008, BMJ.
[61] Douglas G Altman,et al. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement: guidelines for reporting observational studies. , 2014, International journal of surgery.
[62] Bart Post,et al. UvA-DARE ( Digital Academic Repository ) Clinimetrics , clinical profile and prognosis in early Parkinson ’ s disease , 2009 .
[63] M. Levine,et al. Outcomes of dosage adjustments used to manage antiretroviral drug interactions. , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[64] J. Magaziner,et al. Inappropriate Drug Use and Risk of Transition to Nursing Homes Among Community-Dwelling Older Adults , 2006, Medical care.
[65] D. Goldfarb. Patients at the centre: in our practice, and in our use of language , 2004, ACP journal club.
[66] C. Fletcher,et al. Antiviral dynamics and sex differences of zidovudine and lamivudine triphosphate concentrations in HIV-infected individuals , 2003, AIDS.
[67] David Moher,et al. Towards complete and accurate reporting of studies of diagnostic accuracy: the STARD initiative. Standards for Reporting of Diagnostic Accuracy. , 2003, Clinical chemistry.
[68] J. Olsen,et al. Upper gastrointestinal bleeding among users of NSAIDs: a population-based cohort study in Denmark. , 2002, British journal of clinical pharmacology.
[69] Robert E. Anderson,et al. Accuracy in equianalgesic dosing. conversion dilemmas. , 2001, Journal of pain and symptom management.
[70] M. Stewart. Towards a global definition of patient centred care , 2001, BMJ : British Medical Journal.
[71] A. Hartz,et al. A comparison of observational studies and randomized, controlled trials , 2000, American journal of ophthalmology.
[72] M Schulzer,et al. Reporting risks and benefits of therapy by use of the concepts of unqualified success and unmitigated failure: applications to highly cited trials in cardiovascular medicine. , 1999, Circulation.
[73] M. Schulzer,et al. 'Unqualified success' and 'unmitigated failure': number-needed-to-treat-related concepts for assessing treatment efficacy in the presence of treatment-induced adverse events. , 1996, International journal of epidemiology.